These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28561276)

  • 41. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatitis C virus genotypes and risk of cirrhosis in southern Italy.
    Osella AR; Misciagna G; Guerra V; Elba S; Buongiorno G; Cavallini A; Di Leo A; Sonzogni L; Mondelli MU; Silini EM
    Clin Infect Dis; 2001 Jul; 33(1):70-5. PubMed ID: 11389497
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analysis of Plasma Tenascin-C in Post-HCV Cirrhosis: A Prospective Study.
    Benbow JH; Elam AD; Bossi KL; Massengill DL; Brandon-Warner E; Anderson WE; Culberson CR; Russo MW; deLemos AS; Schrum LW
    Dig Dis Sci; 2018 Mar; 63(3):653-664. PubMed ID: 29330728
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
    Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
    Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis.
    Bajaj JS; Fagan A; Sikaroodi M; White MB; Sterling RK; Gilles H; Heuman D; Stravitz RT; Matherly SC; Siddiqui MS; Puri P; Sanyal AJ; Luketic V; John B; Fuchs M; Ahluwalia V; Gillevet PM
    Liver Transpl; 2017 Jul; 23(7):907-914. PubMed ID: 28240840
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France.
    Larsen C; Bousquet V; Delarocque-Astagneau E; Pioche C; Roudot-Thoraval F; ; ; Desenclos JC
    J Med Virol; 2010 Oct; 82(10):1647-54. PubMed ID: 20827760
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease.
    Pramoolsinsap C; Poovorawan Y; Sura T; Theamboonlers A; Busagorn N; Kurathong S
    Southeast Asian J Trop Med Public Health; 1998 Sep; 29(3):480-90. PubMed ID: 10437943
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Polymorphisms of the NS3 Proteins of Hepatitis C Virus Genotype 1b Are Associated with Liver Cirrhosis.
    Chen X; Gui X; Deng L; Ho WZ; Zhou L; Liu Z; Zheng S
    AIDS Res Hum Retroviruses; 2016 Sep; 32(9):892-4. PubMed ID: 27118612
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy.
    Maylin S; Laouénan C; Martinot-Peignoux M; Panhard X; Lapalus M; Nicolas-Chanoine MH; Bedossa P; Asselah T; Marcellin P
    J Clin Virol; 2012 Jan; 53(1):43-7. PubMed ID: 22099210
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Investigation of etiology-specific alterations in the gut microbiota in liver cirrhosis.
    Naseri M; Houri H; Yadegar A; Asadzadeh Aghdaei H; Zahiri J
    Expert Rev Gastroenterol Hepatol; 2021 Dec; 15(12):1435-1441. PubMed ID: 34632902
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alterations of intestinal microbiota in liver cirrhosis with muscle wasting.
    Ren X; Hao S; Yang C; Yuan L; Zhou X; Zhao H; Yao J
    Nutrition; 2021 Mar; 83():111081. PubMed ID: 33348106
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the gut microbe profiles and numbers between patients with liver cirrhosis and healthy individuals.
    Liu J; Wu D; Ahmed A; Li X; Ma Y; Tang L; Mo D; Ma Y; Xin Y
    Curr Microbiol; 2012 Jul; 65(1):7-13. PubMed ID: 22484797
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alterations of the Treatment-Naive Gut Microbiome in Newly Diagnosed Hepatitis C Virus Infection.
    Sultan S; El-Mowafy M; Elgaml A; El-Mesery M; El Shabrawi A; Elegezy M; Hammami R; Mottawea W
    ACS Infect Dis; 2021 May; 7(5):1059-1068. PubMed ID: 33119247
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alterations of the human gut microbiome in liver cirrhosis.
    Qin N; Yang F; Li A; Prifti E; Chen Y; Shao L; Guo J; Le Chatelier E; Yao J; Wu L; Zhou J; Ni S; Liu L; Pons N; Batto JM; Kennedy SP; Leonard P; Yuan C; Ding W; Chen Y; Hu X; Zheng B; Qian G; Xu W; Ehrlich SD; Zheng S; Li L
    Nature; 2014 Sep; 513(7516):59-64. PubMed ID: 25079328
    [TBL] [Abstract][Full Text] [Related]  

  • 55. When pathogenic bacteria meet the intestinal microbiota.
    Rolhion N; Chassaing B
    Philos Trans R Soc Lond B Biol Sci; 2016 Nov; 371(1707):. PubMed ID: 27672153
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Comparative analysis of intestinal microbiota distribution characteristics based on metagenomics in patients with hepatitis B cirrhosis with or without ascites].
    Luan YT; Liu CH; Jiang SL; Gu HT; Lyu J; Xing F; Zhao CQ; Yuan JL; Liu P; Mu YP
    Zhonghua Gan Zang Bing Za Zhi; 2023 Sep; 31(9):974-985. PubMed ID: 37872094
    [No Abstract]   [Full Text] [Related]  

  • 57. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function.
    Bajaj JS; Cox IJ; Betrapally NS; Heuman DM; Schubert ML; Ratneswaran M; Hylemon PB; White MB; Daita K; Noble NA; Sikaroodi M; Williams R; Crossey MM; Taylor-Robinson SD; Gillevet PM
    Am J Physiol Gastrointest Liver Physiol; 2014 Nov; 307(10):G951-7. PubMed ID: 25258407
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Advances in Gut Microbiota of Viral Hepatitis Cirrhosis.
    Wang Y; Pan CQ; Xing H
    Biomed Res Int; 2019; 2019():9726786. PubMed ID: 31886272
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of fecal microbial communities in patients with liver cirrhosis.
    Chen Y; Yang F; Lu H; Wang B; Chen Y; Lei D; Wang Y; Zhu B; Li L
    Hepatology; 2011 Aug; 54(2):562-72. PubMed ID: 21574172
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach.
    Wei X; Yan X; Zou D; Yang Z; Wang X; Liu W; Wang S; Li X; Han J; Huang L; Yuan J
    BMC Gastroenterol; 2013 Dec; 13():175. PubMed ID: 24369878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.